Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover extension study of KN026 and/or KN046 for patients benefiting from prior studies
CTR20221864Phase 2Active
- Sponsor
- Alphamab Oncology
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, erfonrilimab in breast cancer, gastric cancer (GC), esophagogastric junction cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Alphamab Oncology. Started Nov 2022; status: active.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
breast cancergastric cancer (GC)esophagogastric junction cancernon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221864.